These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 12809068

  • 1. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I, Szánthó A, Mayer A, Thurzó L, Pulay T.
    Orv Hetil; 2003 May 11; 144(19):919-24. PubMed ID: 12809068
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 11; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 3. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Oct 11; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 4. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct 11; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 5. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G.
    Acta Obstet Gynecol Scand; 2008 Oct 11; 87(12):1343-52. PubMed ID: 18951208
    [Abstract] [Full Text] [Related]

  • 6. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    J Clin Oncol; 2006 Feb 01; 24(4):579-86. PubMed ID: 16446330
    [Abstract] [Full Text] [Related]

  • 7. Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer.
    Brown JV, Rettenmaier MA, Dillman RA, Birk CL, Culkin K, Micha JP.
    Gynecol Oncol; 1998 Feb 01; 68(2):166-8. PubMed ID: 9514805
    [Abstract] [Full Text] [Related]

  • 8. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
    Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda B, Ghatage P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D'Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA.
    J Natl Cancer Inst; 2010 Oct 20; 102(20):1547-56. PubMed ID: 20937992
    [Abstract] [Full Text] [Related]

  • 9. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD, Zhang Q, Zhang Y.
    Ai Zheng; 2005 Aug 20; 24(8):1002-5. PubMed ID: 16086882
    [Abstract] [Full Text] [Related]

  • 10. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA.
    BMC Cancer; 2006 Sep 25; 6():228. PubMed ID: 16999858
    [Abstract] [Full Text] [Related]

  • 11. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb 25; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M, GRACES Clinical Trial Consortium.
    Gynecol Oncol; 2008 May 25; 109(2):174-81. PubMed ID: 18314182
    [Abstract] [Full Text] [Related]

  • 13. [Evaluation of progression-free interval in patients with ovarian cancer treated by first-line chemotherapy with paclitaxel and carboplatin].
    Lehoczky O, Pulay T.
    Magy Onkol; 2005 May 25; 49(4):315-8. PubMed ID: 16518475
    [Abstract] [Full Text] [Related]

  • 14. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
    Schink JC, Weller E, Harris LS, Cella D, Gerstner J, Falkson C, Wadler S.
    Cancer J; 2001 May 25; 7(2):155-64. PubMed ID: 11324769
    [Abstract] [Full Text] [Related]

  • 15. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
    De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S.
    J Clin Oncol; 2004 Jul 01; 22(13):2635-42. PubMed ID: 15226331
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T, Menczer J, Bernstein RM, Shpigel S, Matcejevsky D, Inbar MJ, Golan A, Grisaru D, Levy T.
    Gynecol Oncol; 2009 Aug 01; 114(2):215-8. PubMed ID: 19446318
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T, Vance RB, McGuire WP, Hoskins WJ, Brady M.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [Abstract] [Full Text] [Related]

  • 20. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.